Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26008037 | 0.85 | IDO1 (0.33) | IDO1TDO2 | |
| SCHEMBL7075276 | 0.83 | IDO1 (0.32) | IDO1TDO2 | |
| SCHEMBL17748237 | 0.82 | IDO1 (0.33) | IDO1TDO2 | |
| SCHEMBL21313314 | 0.82 | IDO1 (0.33) | IDO1TDO2 | |
| SCHEMBL3875354 | 0.82 | L3MBTL1 (0.40) | IDO1TDO2L3MBTL1 | |
| SCHEMBL10887105 | 0.82 | IDO1 (0.33) | IDO1TDO2 | |
| SCHEMBL31367956 | 0.82 | L3MBTL1 (0.40) | IDO1TDO2L3MBTL1 | |
| SCHEMBL187891 | 0.82 | L3MBTL1 (0.40) | IDO1TDO2L3MBTL1 | |
| SCHEMBL3872659 | 0.82 | L3MBTL1 (0.40) | IDO1TDO2L3MBTL1 | |
| SCHEMBL3872657 | 0.82 | L3MBTL1 (0.40) | IDO1TDO2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | IDO1 4758/4885TDO2 4778/4885L3MBTL1 4300/4885 |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | IDO1 4546/4885TDO2 4872/4885L3MBTL1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.